Last reviewed · How we verify
JCAR017
JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.
JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | JCAR017 |
|---|---|
| Also known as | Lisocabtagene Maraleucel (liso-cel) |
| Sponsor | Celgene |
| Drug class | CAR T-cell therapy |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
JCAR017 involves genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen found on the surface of B cells, leading to the destruction of CD19-positive cells, including cancerous B cells in certain types of lymphoma.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Cytokine release syndrome
- Neurological events
Key clinical trials
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (PHASE2)
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (PHASE1, PHASE2)
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome (PHASE2)
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (PHASE2)
- ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma (PHASE1, PHASE2)
- Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JCAR017 CI brief — competitive landscape report
- JCAR017 updates RSS · CI watch RSS
- Celgene portfolio CI